Theragnostics

Theragnostics serves the United States through its office located in Boston, Massachusetts. The goal is to provide a complete portfolio to transform patient care, from initial diagnosis to treatment, including treatment planning and monitoring. At the core of this strategy is Gallia® , a revolutionary PET Gallium-68 diagnostic and radionuclide therapy technology. The most advanced product is THG-001, also known as Ga-68 THP-PSMA, which is currently in clinical development.